{"filing":{"accession_number":"0001326190-26-000044","cik":"0001326190","ticker":"ALT","company_name":"Altimmune, Inc.","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"alt-20260728x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/alt-20260728x8k.htm"},"events":[{"id":20890,"run_id":18810,"accession_number":"0001326190-26-000044","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder, meeting its primary endpoint with statistically significant reduction in heavy drinking days and secondary endpoints recognized by the FDA as registrational endpoints. The company plans to hold an End-of-Phase 2 FDA meeting to discuss the regulatory pathway forward.","company_name":"Altimmune, Inc.","ticker":"ALT","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20392,"accession_number":"0001326190-26-000044","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder, meeting its primary endpoint with statistically significant reduction in heavy drinking days and secondary endpoints recognized by the FDA as registrational endpoints. This is a material clinical milestone for a late-stage biopharmaceutical company, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant clinical development milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:05:44.873117+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20393,"accession_number":"0001326190-26-000044","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder, meeting its primary endpoint with statistically significant reduction in heavy drinking days and positive secondary endpoints. This is a material clinical milestone for a late-stage biopharmaceutical company, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure centers on a significant clinical development milestone and regulatory pathway decision (planning an End-of-Phase 2 FDA meeting), making it an operational/strategic business event material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:05:44.873117+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20392,"accession_number":"0001326190-26-000044","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder, meeting its primary endpoint with statistically significant reduction in heavy drinking days and secondary endpoints recognized by the FDA as registrational endpoints. This is a material clinical milestone for a late-stage biopharmaceutical company, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant clinical development milestone that would affect investor assessment of the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:05:44.873117+00:00","company_name":"Altimmune, Inc.","ticker":"ALT","filing_date":"2026-07-28"},{"id":20393,"accession_number":"0001326190-26-000044","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder, meeting its primary endpoint with statistically significant reduction in heavy drinking days and positive secondary endpoints. This is a material clinical milestone for a late-stage biopharmaceutical company, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure centers on a significant clinical development milestone and regulatory pathway decision (planning an End-of-Phase 2 FDA meeting), making it an operational/strategic business event material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:05:44.873117+00:00","company_name":"Altimmune, Inc.","ticker":"ALT","filing_date":"2026-07-28"}]}